{
    "2020-12-06": [
        [
            {
                "time": "",
                "original_text": "沃森生物贱卖上海润泽背后：资产剥离时机和交易估值皆存疑 资产异常",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "贱卖",
                        "上海润泽",
                        "资产剥离",
                        "交易估值",
                        "资产异常"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "2021年医药生物行业策略报告：聚焦黄金赛道 寻找疫后高光",
                "features": {
                    "keywords": [
                        "2021年",
                        "医药生物",
                        "行业策略",
                        "黄金赛道",
                        "疫后高光"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}